Cervical cancer is often a slowly progressing malignancy that presents in women with a mean age of 51. This case is a highly unusual presentation of metastatic squamous cell carcinoma (SCC).
Case:
A 28-year-old healthy, gravida 0, female—who was post a quadrivalent Gardasil® series with normal Papanicolaou smears—presented with abdominal pain, bloating, and postcoital bleeding. A colposcopy was significant for cervical intraepithelial neoplasia III. Cold knife cone was significant for SCC with positive margins. Human papilloma virus (HPV) typing was positive for HPV 31 and 68. Positron emission tomography was negative for metastasis. However, a radical hysterectomy started and then was abandoned due to the discovery of metastases to the sigmoid epiploica.
Results:
Pathology testing revealed that this patient had SCC with metastasis to the sigmoid epiploica and to 2 pelvic lymph nodes. Immunohistochemical staining was positive for p16. She was diagnosed with stage IVA SCC of the cervix and, as of this writing, stated that she intended to undergo radiation therapy followed by chemotherapy.
Conclusions:
When appropriate, a high index of suspicion is necessary to diagnose cervical cancer in low-risk individuals. (J GYNECOL SURG 34:159)
JunjegaA, SehgalA, MitraAB, PandeyA. A survey on risk factors associated with cervical cancer. Indian J Cancer, 2003; 40:15.
4.
LouieKS, de SanjoseS, DiazM, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer, 2009; 100:1191.
5.
DuguéP, ReboljM, GarredP, LyngeE. Immunosuppression and risk of cervical cancer. Expert Rev Anticancer Ther, 2013; 13:29.
6.
LeeYC, HashibeM. Tobacco, alcohol, and cancer in low and high income countries. Ann Glob Health, 2014; 80:378.
7.
MittendorfR. Teratogen update: Carcinogenesis and teratognesis associated with exposure to diethylstilbestrol (DES) in utero. Teratology, 1995; 51:435.
8.
FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med, 2007; 356:1915.
9.
AultKA; FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like–particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet, 2007; 369:1861.
10.
GarlandSM, Hernandez-AvilaM, WheelerCMet al.; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med, 2007; 356:1928.
11.
PaavonenJ, JenkinsD, BoschFX, et al.; HPV PATRICIA Study Group. Efficacy of a prophylactic adjuvant bivalent L1 virus-like–particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet, 2007; 369:2161.
12.
PratJ, FranceschiS. Cancers of the female reproductive organs. In: StewartBW, WildCP, eds. World Cancer Report, 2014. Lyon: International Agency for Research on Cancer, 2014:465.
13.
IniestaMD, SchmeierKM, RamirezPT. Tumors of the uterine cervix. In: KantarjianHM, WolffRA, eds. The MD Anderson Manual of Medical Oncology, 3rd ed. New York: McGraw-Hill Education, 2016: 689.
14.
RiesLAG, MelbertD, KrapchoM, et al.SEER Cancer Statistics Review, 1975–2004. Bethesda, MD: National Cancer Institute, 2007.
15.
RichardsonDL. Cervical cancer. In: HoffmanBL, SchorgeJO, BradshawKD, HalvorsonLM, SchafferJI, CortonMM, eds; Calver LE (Atlas Art Director). Williams Gynecology, 3rd ed. New York: McGraw-Hill Education, 2016:657.
16.
QuinnMA, BendetJL, OdicinoF, et al.Carcinoma of the cervix uteri: FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet, 2006; 95(suppl1):S43.
17.
CallahanTL, et al.Cervical neoplasia and cervical cancer. In: CallahanT.L., CaugheyAB, eds. Blueprints Obstetrics and Gynecology, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2008: 298.
18.
LiN, FranceschiS, Howell-JonesR, SnijdersPJ, CliffordGM. Human papilloma virus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer, 2011; 128:927.
19.
ChanSY, DeliusH, HalpernAL, BernardHU. Analysis of genomic sequences of 95 papillomavirus types: Uniting typing, phylogeny, and taxonomy. J Virol, 1995; 69:3074.
20.
CliffordGM, SmithJS, PlummerM, MuñozN, FranceschiS. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer, 2003; 88:63.
21.
de CremouxP, de la RochefordièreA, SavignoniA, et al.Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype. Int J Cancer, 2009; 124:778.
22.
van BommelPF, van den BruleAJ, HelmerhorstTJ, et al.HPV DNA presence and HPV genotypes as prognostic factors in low-stage squamous cell cervical cancer. Gynecol Oncol, 1993; 48:333.
23.
WalkerJ, BlossJD, LiaoSY, BermanM, BergenS, WilczynskiSP. Human papillomavirus genotype as a prognostic indicator in carcinoma of the uterine cervix. Obstet Gynecol, 1989; 74:781.
24.
HuangLW, ChaoSL, HwangJL. Human papillomavirus-31–related types predict better survival in cervical carcinoma. Cancer, 2004; 100:327.
25.
BarutMU, KaleA, KuyumcuoğluU, BozkurtM, AğaçayakE, ÖzekinciS, GülT. Analysis of sensitivity, specificity, and positive and negative predictive values of smear and colposcopy in diagnosis of premalignant and malignant cervical lesions. Med Sci Monit, 2015; 21:3860.
26.
TaoX, GriffithCC, ZhouX, WangZ, YanY, LiZ, ZhaoC. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: Experience from the largest women's hospital in China. Cancer Cytopathol, 2015; 123:421.
27.
American College of Obstetricians and Gynecologists. Committee opinion no. 704: Human papillomavirus vaccination. Obstet Gynecol, 2017; 129:1155.
28.
PetroskyE, BocchiniJAJr, HaririS, et al.Centers for Disease Control and Prevention. Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep, 2015; 64:300.
29.
TjalmaWA. There are two prophylactic human papillomavirus vaccines against cancer, and they are different. J Clin Oncol, 2015; 33:964.
30.
LuB, KumarA, CastellsaqueX, GiulianoAR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: A systematic review & meta-analysis. BMC Infect Dis, 2001; 11:13.
31.
GiulianoAR, PalefskyJM, GoldstoneS, et al.Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med, 2011; 364; 40;erratum in: N Engl J Med, 2011; 364:1481.
